Clinical Course of Rattlesnake Bite Victims Treated without Antivenom
A Thesis submitted to The University of Arizona College of Medicine - Phoenix in partial fulfillment of the requirements for the Degree of Doctor of Medicine. === The standard treatment for rattlesnake envenomation (RSE) is antivenom. The clinical course of patients treated with antivenom is well d...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_US |
| Published: |
The University of Arizona.
2018
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10150/627152 http://arizona.openrepository.com/arizona/handle/10150/627152 |
| Summary: | A Thesis submitted to The University of Arizona College of Medicine - Phoenix in partial fulfillment of the requirements for the Degree of Doctor of Medicine. === The standard treatment for rattlesnake envenomation (RSE) is antivenom.
The clinical course of patients treated with antivenom is well described.
Prior to 2000, only a whole IgG AV (IgGAV) associated with high rates of
hypersensitivity reactions (HSS) was available to treat RSE. Since 2000,
Crotalidae Polyvalent Immune Fab (FabAV), which has a better safety profile
than IgGAV, has been primarily used.
Patients with RSE may not be treated with AV for a variety of reasons
including history or perceived risk of HSS, patient refusal, drug shortage, or
clinical impression that AV is not indicated.
Research Question: What outcomes are associated with moderate to severe
RSEs treated without antivenom? |
|---|